ER-POSITIVE BREAST CANCER
Clinical trials for ER-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo offers hope for breast cancer that stopped responding to standard therapy
Disease control Recruiting nowThis study tests a two-drug combination (fulvestrant and abemaciclib) in people with a common type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a standard treatment (a CDK4/6 inhibitor). The goal is to see if taking a break from the previo…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New hope for advanced breast cancer: phase 3 trial of OP-1250 launches
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against standard hormone therapies for people with a common type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than current options. About 510 adults whose cancer worse…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for advanced breast cancer: drug combo trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called OP-1250 combined with other targeted therapies (ribociclib, alpelisib, everolimus, or atirmociclib) in adults with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for s…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC